HDFC Pharma and Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 21-02-2025
₹ 15.43
▲0.7%
1D
Inception Returns
38.8%
/yr
About HDFC Pharma and Healthcare Fund Direct Growth
HDFC Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 4 October, 2023. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- HDFC Pharma and Healthcare Fund Direct Growth has ₹1568 Cr worth of assets under management (AUM) as on Jan 2025 and is less than category average.
- The fund has an expense ratio 1.
Returns
HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 38.83% since inception. Over the last 1 year the fund has given a CAGR return of 24.71%.
Holdings
HDFC Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Health, Corporate, Cash Equivalent, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Cipla Ltd, Lupin Ltd, Max Healthcare Institute Ltd Ordinary Shares
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of HDFC Pharma and Healthcare Fund Direct Growth
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. HDFC Pharma and Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
INDmoney Rank for HDFC Pharma and Healthcare Fund Direct Growth
HDFC Pharma and Healthcare Fund Direct Growth Overview
| Expense ratio | 0.97% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹1568 Cr |
| Inception Date | 4 October, 2023 |
| Min Lumpsum/SIP | ₹100/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 28.39% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (21-Feb-25)
Fund Distribution
as on (31-Jan-25)
- AUM of the fund stands at 1.6K Cr as of Jan'25
- AUM increased by 117.5 Cr between Jan'25 and Dec'24
Top 3 Sectors in January were Health, Corporate & Basic Materials
Top Growth Drivers | 1M Return |
|---|---|
 Ami Organics Ltd | 8.5% |
 Bajaj Healthcare Ltd | 6.3% |
HDFC Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
About the fund
Fund Allocations
AUM size ₹1568 Cr
Expense Ratio 0.97%
Frequently Asked Questions for HDFC Pharma and Healthcare Fund Direct Growth
HDFC Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -5.26% | -5.26% |
6 Month Returns | 2.23% | 2.23% |
1 Year Returns | 24.71% | 24.71% |
3 Years Returns | 0% | 0% |
5 Years Returns | 0% | 0% |
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | 8.07 | - | - |
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | 0.97 | - | - |
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | 1.52 | - | - |
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | 15.71 | - | - |